Noemi Reguart
@NReguart
Followers
4K
Following
10K
Media
403
Statuses
4K
MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM
Sitges, España
Joined March 2017
Out now! New Spanish language episode of #LungCancerConsidered. @NarjustFlorezMD talks with @moniccastrog, @loladelamata, and @maritza_rramos about #lungcancer in women, risk factors, inequities, and their professional journeys. Listen now➡️ https://t.co/8FigIKQN3C
0
10
20
Poster session of #NACLC25 - update on pralsetinib in RET fusion NSCLC (ARROW trial) in pts with prior immunotherapy. RR 64%, DCR 91%, mOS 30.9m with no AEs of hypersensitivity reported. Grateful to be included in this subanalysis.
1
10
35
Poster session of #NACLC25 - glad to present a Trials in Progress poster of the ROSETTA Lung-02 trial: first-line pumitamig (BNT327/BMS986545 - a PD-L1 x VEGF bispecific antibody) + chemotherapy in advaned NSCLC. Design for this phase II/III trial shown here.
0
8
31
Rest in peace, my friend. You’ll be deeply missed, and your legacy will always live on with us.
.@anguspratt was a giant in the lung cancer community. An advocate, friend, and warm, unforgettable presence. His legacy lives on in the research and advocacy he championed. We feel the weight of his loss, and we’ll continue the work that meant so much to him.
0
2
9
Controversies and open questions in SCLC: PS2, PCI, biomarkers… have you ever thought about sequencing SCLC? AMAZING!!! #ESMOPreceptorshipAsia @JordiRemon @myESMO
1
6
35
Love this unique 🇯🇵 perspective on SCLC new treatments by @HHorinouchi @myESMO #ESMOpreceptorship2025
0
3
20
Superb state-of-the-art overview of perioperative TKIs and the importance of genomic testing in NSCLC by @HHorinouchi at @myESMO #ESMOPreceptorshipAsia
0
6
30
After a superb ESMO Asia meeting #ESMOAsia2025 , it's time to start the ESMO Lung Preceptorship with our Asian colleagues... a comprehensive program and exchanges that promise to be rich...@myESMO @peters_solange @HendriksLizza
0
6
22
Brilliant talk by Prof. Pan-Chyr Yang on air pollution, genetics, lung cancer, and screening in Asia at the #ESMOPreceptorshipAsia. @myESMO
0
4
22
🙌Today, we witnessed the power of togetherness at #ESMOAsia25. Crowded rooms, meaningful discussions, and groundbreaking research, all united by one mission: improving patient outcomes in Asia. #esmomeetings 👉 Together, we shape the future of oncology: https://t.co/2RSGdM1d68
1
11
30
Comprehensive Educational Session at #ESMOASIA2 on EGFR mutant NSCLC. Excellent presentations by @JordiRemon @MarianaBrandao0 @stephanieplsaw Dr Myung-Ju Ahn and Dr Hye Ryun kim.
0
5
24
Don’t miss the Thoracic Malignancies tracks #ESMOASIA25— thrilled and honored to co-chair alongside Dr. Thanyanan Baisamut
📣 ESMO Asia 2025 is here! Join us in Singapore as global experts share the latest insights across 70 sessions and 900+ abstracts. Let’s power progress in oncology—together. #ESMOAsia25 #esmomeetings 🔗 https://t.co/Tt2IgjV8Hp
0
1
14
Felicidades a todos los jovenes premiados pot los mejores trabajos en especial a la Dra. Claudia Miquel y Dra.Arriola Hospital de Mar @gecp_org #16CongressOnLungCancer
0
4
16
📍Dra. @charocampelo (Hospital Univ. de A Coruña) reviews and SoC new prospects on oncogenic fusions in lung cancer ALK, RET, NTRK, ROS1, NRG1, RASGRF2, MET 🙌#16CongressOnLungCancer #LungCancer
0
2
19
â•ď¸Ź Inicia la SESIĂ“N VII: Other Drivers Mutations in Lung Cancer , moderada por el Dr. @bamssutis (Hospital General Univ. Dr. Balmis, Alicante) y la Dra. Teresa Morán (ICO, Hospital Univ. Germans Trias i Pujol, Badalona). ¡Comenzamos la jornada explorando nuevas mutaciones clave
0
1
3
FDA grants accelerated approval to sevabertinib for previously treated HER2 mutant NSCLC. Based on the SOHO-01 trial with RR 71%, DOR 9.2m. Main toxicity is diarrhea, which is very common but tends to be low-grade. Joins zongertinib, T-DXd in the space. https://t.co/yJ8ggXfxwf
fda.gov
On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib.
3
16
42
During Lung Cancer Awareness Month, the EORTC Lung Cancer Group highlights key facts to raise awareness and underline the importance of clinical research. #LungCancerAwarenessMonth #EORTC_LCG
@EORTC
@RobertoFerrara_ @JordiRemon @JcbenitezMD @MarianaBrandao0 @HendriksLizza
0
1
4
A special thank you to @FabioSalomone22 and Giorgia Novero — such a detailed and thoughtful analysis in a field as heterogeneous and still insufficiently standardised as QoL assessment.
HRQoL in early stage NSCLC still underreported. Current QoL tools lack granularity in domains as sleep& sexual life. Assessment timeframes may fail to capture late/chronic QoL effects occurring, especially with ICI, after treatment ends. https://t.co/BMBpAZBZvm
@FabioSalomone22
1
2
8
Why do academic trials matter? Because they answer the real world and translational question changing patient care. Excited for the @EORTC Lung Cancer Group Autumn Meeting on Nov 21 @MOcchipintiMD @RobertoFerrara_ @JordiRemon @MarianaBrandao0
#LungCancerAwarenessMonth #EORTC_LCG
0
2
5
The FDA has granted full approval to Imdelltra for extensive-stage SCLC, based on the Phase 3 DeLLphi-304 trial. A major step forward for patients and clinicians. 👏 Looking forward to EMA’s evaluation. #LungCancer #SCLC
amgen.com
2
5
27